JPH02300136A - Immunological enhancing agent - Google Patents
Immunological enhancing agentInfo
- Publication number
- JPH02300136A JPH02300136A JP1119497A JP11949789A JPH02300136A JP H02300136 A JPH02300136 A JP H02300136A JP 1119497 A JP1119497 A JP 1119497A JP 11949789 A JP11949789 A JP 11949789A JP H02300136 A JPH02300136 A JP H02300136A
- Authority
- JP
- Japan
- Prior art keywords
- glabla
- glycyrrhiza
- polysaccharide
- activity
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 230000001900 immune effect Effects 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229920001284 acidic polysaccharide Polymers 0.000 claims abstract description 15
- 150000004805 acidic polysaccharides Chemical class 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 11
- 241000202807 Glycyrrhiza Species 0.000 claims abstract 8
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 12
- 239000003623 enhancer Substances 0.000 claims description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 11
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 11
- 229940010454 licorice Drugs 0.000 claims description 11
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 48
- 229920001282 polysaccharide Polymers 0.000 abstract description 16
- 239000005017 polysaccharide Substances 0.000 abstract description 16
- 150000004804 polysaccharides Chemical class 0.000 abstract description 16
- 239000003226 mitogen Substances 0.000 abstract description 11
- 239000002244 precipitate Substances 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 abstract description 2
- 229920001503 Glucan Polymers 0.000 abstract description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 abstract description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 abstract description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 abstract description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 abstract description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 abstract description 2
- 239000006103 coloring component Substances 0.000 abstract description 2
- 229930182830 galactose Natural products 0.000 abstract description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 abstract 6
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000003544 deproteinization Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 description 14
- 244000025254 Cannabis sativa Species 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 240000004670 Glycyrrhiza echinata Species 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 230000003213 activating effect Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 230000016784 immunoglobulin production Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229910052722 tritium Inorganic materials 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229920001491 Lentinan Polymers 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002305 Schizophyllan Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000035584 blastogenesis Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002766 immunoenhancing effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229940115286 lentinan Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 108010001062 polysaccharide-K Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012513 sanitation solution Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、li草中の酸性多糖を免疫増強剤として用い
ることに関するものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to the use of acidic polysaccharide in Lili grass as an immune enhancer.
〔従来の技術および発明が解決しようとする課題〕生体
は、主として免疫系の作用によって細菌やウィルス等の
微生物、あるいは寄生虫の攻撃から守られている。[Prior Art and Problems to be Solved by the Invention] Living organisms are protected from attack by microorganisms such as bacteria and viruses, or by parasites, mainly by the action of the immune system.
また、癌の自然退縮はまれな現象ではなく、どちらかと
いえば日常のありふれた現象といってもよい。この知見
は、癌に対する免疫応答の存在を示唆するものである。Furthermore, spontaneous regression of cancer is not a rare phenomenon, but rather a common phenomenon in everyday life. This finding suggests the existence of an immune response to cancer.
従って、免疫系を活性化あるいは増強することにより、
宿主の抵抗性が向上し、ひいては感染症や癌の予防・治
療も期待できると思われる。Therefore, by activating or strengthening the immune system,
It is believed that host resistance will be improved, and that it may also be possible to prevent and treat infectious diseases and cancer.
このような背景から、クレスチン、レンチナン、シゾフ
ィランの3種の多糖体制病剤(免疫療法剤)が開発され
、今日では大型薬品に成長しているが、現在までのとこ
ろ、これらの薬剤は抗癌剤として認可されているに過ぎ
ない。Against this background, three types of polysaccharide systemic disease agents (immunotherapy agents), Krestin, lentinan, and schizophyllan, were developed and have grown into major drugs today, but to date, these drugs have not been effective as anticancer agents. It's just sanctioned.
しかしながら、多糖体には抗癌効果以外の免疫増強作用
についても、相当数の報告があり、抵抗力の増強や感染
症の予防・治療といった1」的で使用することも可能で
あると思われる。However, there are a considerable number of reports that polysaccharides have immune-enhancing effects other than anti-cancer effects, and it seems possible to use them for the following purposes, such as increasing resistance and preventing and treating infectious diseases. .
一方、近年、エイズ(後天性免疫不全症候群)が全世界
的な問題となっている。現在までのところ著効な治療薬
は見出されていないが、エイズの性格上、多糖体等の免
疫増強剤はその発症予防や治療にある程度有効であると
思われる。Meanwhile, in recent years, AIDS (acquired immunodeficiency syndrome) has become a worldwide problem. To date, no effective therapeutic drug has been found, but due to the nature of AIDS, immune enhancers such as polysaccharides are thought to be effective to some extent in preventing and treating the disease.
そこで新規でより有効な免疫増強剤を得るべく種々の酵
母及び生薬から抽出した多糖体画分の免疫系に及ぼす影
響をマイト−ジエン活性(リンパ球の幼若化反応)を示
標として検討を行った。Therefore, in order to obtain new and more effective immunostimulants, we investigated the effects of polysaccharide fractions extracted from various yeasts and crude drugs on the immune system using mitogen activity (lymphocyte blastogenesis) as an indicator. went.
その結果は草から酢酸酸性下で抽出される両分、特にア
フガニスタン産の甘草(以下アフガンは草と略; G1
7c7r+hirx glxblりの熱水抽出物を除タ
ンパクしアルコールで沈殿させたものを、さらに酢酸で
抽出して得られる両分(以下AL−4と略)に強いマイ
ト−ジエン活性を認めた。 さらに、AL−4には抗体
産生を促進する作用やマクロファージを活性化する作用
があることを見出した。The results showed that the components extracted from grass under acetic acid acidity, especially licorice from Afghanistan (hereinafter afghan abbreviated as grass; G1)
A strong mitodiene activity was observed in both extracts (hereinafter abbreviated as AL-4) obtained by removing protein from a hot water extract of 7c7r+hirx glxbl and precipitating with alcohol, and then further extracting with acetic acid. Furthermore, it was discovered that AL-4 has an effect of promoting antibody production and an effect of activating macrophages.
なお、AL−4は分析の結果、ウロン酸およびグルコー
スて構1戊される酸性多糖が−1,1戊分である。As a result of analysis, AL-4 has an acidic polysaccharide composed of uronic acid and glucose with a concentration of -1.1.
また以前、甘草から抽出した中性多糖が免疫増強作用を
示すことが、千葉人の熊谷らによって報告されているが
し和漢薬、I+、 ?9 (+97811、AL−、l
とは明らかに異なるものである。In addition, Kumagai et al. from Chiba have previously reported that neutral polysaccharide extracted from licorice has an immune-enhancing effect. 9 (+97811, AL-, l
This is clearly different.
以上の結果から、甘草、特にアワガン11草の酸性多糖
は強く免疫系を活性化する作用があることが判明し、本
発明を完成した。From the above results, it has been found that the acidic polysaccharide of licorice, especially silver lily, has a strong effect of activating the immune system, and the present invention has been completed.
本発明におけるAL−4のマイト−ジエン活性、抗体産
生促進活性、マクロファージ活性化の試験方法ならびに
その結果を以上に示す。The methods and results for testing the mitogen activity, antibody production promoting activity, and macrophage activation of AL-4 in the present invention are shown above.
(1)マイト−ジエン活性試験
96穴プレートにマウスの肝臓細胞と試料を加え、20
時間培養した後、トリチウムチミジンを添加し、さらに
4時間培養する。そして細胞を濾紙上に採取し、細胞に
取り込まれた1トリチウムを液体シンチレーションカウ
ンターで測定することによりマイト−ジエン活性を判定
した。なお、マイト−ジエン活性物質としてConA
(コンカナバリンA)とLPS(リポ多糖)と比較した
。(1) Mitogen activity test Add mouse liver cells and samples to a 96-well plate,
After culturing for an hour, tritium thymidine is added and the culture is further cultured for 4 hours. Then, the cells were collected onto a filter paper, and the mitogen activity was determined by measuring the amount of tritium incorporated into the cells using a liquid scintillation counter. In addition, ConA is used as a mitogen active substance.
(concanavalin A) and LPS (lipopolysaccharide).
分析法は、ウロン酸についてはカルバゾール・硫酸法、
グルコース等の中性糖についてはトリフルオロ酢酸処理
後、液体クロマトグルフィーによりそれぞれ定量した。The analytical method is the carbazole/sulfuric acid method for uronic acid;
Neutral sugars such as glucose were quantified by liquid chromatography after treatment with trifluoroacetic acid.
マイト−ジエン活性は、コントロールを1とした時のト
リチウムチミジンの取り込みで示す。Mito-diene activity is expressed as tritiated thymidine incorporation relative to control.
結果を表1に示す。The results are shown in Table 1.
表 1
試料(pg/*l) マイト−ジエン活性AL−/
l 1 2〜4
1010〜20
100 30〜50
新種は草多糖 1 1〜2
10 5〜10
IQo 10〜20
ConA 2 2G〜40L
P 3 5 15〜30表1に示
した結果から、AL−4に強いマイトーンエン活性があ
ることが明らかとなった。しかもその活性は、ConA
’?? L P Sの至適活性よりも優れているもの
と推定された。Table 1 Sample (pg/*l) Mito-diene activity AL-/
l 1 2-4 1010-20 100 30-50 The new species is grass polysaccharide 1 1-2 10 5-10 IQo 10-20 ConA 2 2G-40L
P 3 5 15-30 From the results shown in Table 1, it became clear that AL-4 had strong mitoneene activity. Moreover, its activity is ConA
'? ? It was estimated that this activity was superior to the optimal activity of LPS.
また同様の条件で調製した中国新種産の11草よりの試
料と比べ2倍以上強い活性を示した。It also showed more than twice the activity as samples from 11 new varieties of Chinese plants prepared under similar conditions.
(1)抗体産生促進活性試験
96穴プレートにマウスのl1ii臓細胞と試料を加え
、48時間培養した後、培養上清を採取する。そして、
その培養上清中の抗体(rgM)をEL I SA法で
定量することにより判定した。(1) Antibody Production Promotion Activity Test Add mouse 11I visceral cells and a sample to a 96-well plate, culture for 48 hours, and then collect the culture supernatant. and,
The determination was made by quantifying the antibody (rgM) in the culture supernatant using the ELISA method.
結果を表2に示す。The results are shown in Table 2.
表 2
AL−4r gM爪
020〜60
150〜100
10 200〜400
+00 > 500
n=3
表2に示した結果から、AL−4は抗体産生を促進する
作用があることがわかった。Table 2 AL-4r gM Nail 020-60 150-100 10 200-400 +00 > 500 n=3 From the results shown in Table 2, it was found that AL-4 has the effect of promoting antibody production.
(3)マクロファージの活性化試験
マクロファージの活性化は、グルコースの消費促進を指
標として試験した。すなわち、チオグリコレート培地で
誘導したマウス腹くう内滲出細胞に試料を加え、24時
間後の培養上清中のグルコースを定量し、その消費率を
求めることにより、マクロファージの活性化を判定した
。(3) Macrophage activation test Macrophage activation was tested using promotion of glucose consumption as an indicator. That is, macrophage activation was determined by adding a sample to mouse intraperitoneal exudate cells induced with thioglycollate medium, quantifying glucose in the culture supernatant after 24 hours, and determining its consumption rate.
結果を表3に示す。The results are shown in Table 3.
表 3
AL−4グルコース消費率
0 5〜10
t IQ〜20
1010〜20
表3に示した結果から、アフガンは草から抽出した酸性
多糖を主成分とするΔL−4はマクロファージを活性化
する作用があることがわかった。Table 3 AL-4 glucose consumption rate 0 5-10 t IQ ~20 1010-20 From the results shown in Table 3, ΔL-4, whose main component is acidic polysaccharide extracted from Afghan grass, has the effect of activating macrophages. It turns out that there is.
以上の実験結果から明らかなように、本発明のAL−/
Iは種々の免疫増強作用をnすることがわかった。As is clear from the above experimental results, the AL-/
I was found to have various immunoenhancing effects.
以F1実施例により本発明の一部を例示するが、本発明
はこれに限定されるものではない。A part of the present invention will be illustrated below using Example F1, but the present invention is not limited thereto.
実施例1
アフガンは草根の熱水抽出物をpHを2.6に調整し遠
心分離にかけ、その上清をとり、p Hを5.2に調整
、遠心分離により上清を得、そこにメタノールを等爪加
え、遠心分離にかけ、沈殿物をとる。その沈殿物のIN
酢酸抽出物に等はのメタノールを加え、遠心分離し、そ
の沈殿物を水に溶解させ、透析にかけた。そして、その
透析内液よりΔl5−4画分を0.3%の収率で得た。Example 1 Afghani was prepared by adjusting the pH of a hot water extract of grass roots to 2.6, centrifuging it, taking the supernatant, adjusting the pH to 5.2, centrifuging to obtain the supernatant, and adding methanol to it. Add to the solution, centrifuge, and remove the precipitate. IN of that precipitate
Methanol was added to the acetic acid extract, centrifuged, and the precipitate was dissolved in water and subjected to dialysis. A Δl5-4 fraction was obtained from the dialyzed fluid at a yield of 0.3%.
このマイト−ジエン活性は、その濃度が1.10゜10
[1pg/*lの時、それぞれ2.11.34であった
(コントロールを1とした時のトリチウムチミジンの取
り込み)。This mitogen activity is due to its concentration of 1.10°10
[When the concentration was 1 pg/*l, the values were 2.11.34 (incorporation of tritium thymidine when the control was set to 1).
IgMの産生量については、その濃度が1゜10、
tooμg/mlの時、それぞれ71.303. >
500ng/mlであった(コントロールは45ng/
ml)。Regarding the production amount of IgM, its concentration is 1°10,
When tooμg/ml, respectively, 71.303. >
500ng/ml (control was 45ng/ml).
ml).
マクロファージのグルコースのン肖費については、その
濃度が1.10.100μg/wlの時、それぞれ+3
. 15. 18%であった(コントロールは8%)。The glucose concentration of macrophages was +3 when the concentration was 1, 10, and 100 μg/wl, respectively.
.. 15. It was 18% (control: 8%).
手続抑+’を正P饗:(自発)
1.事件の表示
平成1年 特許願 第119497号
2、発明の名称
免疫増強剤
3、補正をする者
事件との関係 特許出願人
住 所 東京都千代[IJ区丸の内−丁目4番5号
名 称 (234)山陽国策バルブ株式会社4、代
理人
住 所 東京都千代田区神10北乗物町16番地〒
101 英ビル3階
明 細 書
■1発明の名称
免疫増強剤
2、特許請求の範囲
(1)甘草、甘草の水抽出物、1を草の含水極性溶媒抽
出物のいずれかの酢酸抽出物を主構成要素とする免疫増
強剤。Procedural restraint +' to be corrected: (spontaneous) 1. Indication of the case 1999 Patent application No. 119497 2, Name of the invention Immune enhancer 3, Person making the amendment Relationship to the case Patent applicant address Chiyo, Tokyo [4-5 Marunouchi-chome, IJ-ku Name ( 234) Sanyo Kokusaku Valve Co., Ltd. 4, Agent Address: 16, Kami 10 Kita-Jimono-cho, Chiyoda-ku, Tokyo
101 3rd floor of Ei Building Description ■1 Name of the invention Immune enhancer 2. Claims (1) Licorice, an aqueous extract of licorice; Immune enhancer as the main component.
(2)甘草の酸性多糖又はこれを含む両分を主構成要素
とする免疫増強剤。(2) An immune enhancer whose main component is acidic polysaccharide of licorice or both components thereof.
(3)甘草がアフガニスタン産の11草(Glyc7r
+hi−xs glabls)である請求項1及び2記
載の免疫増強剤。(3) Licorice is 11 grasses from Afghanistan (Glyc7r
+hi-xs glabls).
3、発明の詳細な説明
〔産業上の利用分野〕
本発明は、け掌中の酸性多糖或はこれを含む両分を免疫
増強剤として用いることに関するものである。3. Detailed Description of the Invention [Industrial Field of Application] The present invention relates to the use of acidic polysaccharides in the palm of the hand or compounds containing the same as immune enhancers.
〔従来の技術および発明が解決しようとする課題〕生体
は、主として免疫系の作用によって細菌やウィルス等の
微生物、あるいは寄生虫の攻撃から守られている。[Prior Art and Problems to be Solved by the Invention] Living organisms are protected from attack by microorganisms such as bacteria and viruses, or by parasites, mainly by the action of the immune system.
また、癌の自然退縮はまれな現象ではなく、どちらかと
いえば日常のありふれた現象といってもよい。この知見
は、癌に対する免疫応答の存在を示唆するものである。Furthermore, spontaneous regression of cancer is not a rare phenomenon, but rather a common phenomenon in everyday life. This finding suggests the existence of an immune response to cancer.
従って、免疫系を活性化あるいは増強することにより、
宿主の抵抗性が向上し、ひいては感染症や癌の予防・治
療も期待できると思われる。Therefore, by activating or strengthening the immune system,
It is believed that host resistance will be improved, and that it may also be possible to prevent and treat infectious diseases and cancer.
このような背景から、クレスチン、レンチナン、シゾフ
ィラン等の多糖体制癌剤(免疫療法剤)が開発され、今
日では大型薬品に成長しているが、現在までのところ、
これらの薬剤は抗癌剤として認可されているに過ぎない
。Against this background, polysaccharide-based cancer drugs (immunotherapy drugs) such as Krestin, Lentinan, and Schizophyllan were developed and have grown into major drugs today.
These drugs are only approved as anticancer agents.
しかしながら、多糖体には抗癌効果以外の免疫増強作用
についても、相当数の報告があり、抵抗力の増強や感染
症の予防・治療といった目的で使用することも可能であ
ると思われる。However, there are a considerable number of reports on polysaccharides having immune-enhancing effects other than anticancer effects, and it seems possible to use them for purposes such as increasing resistance and preventing and treating infectious diseases.
一方、近年、エイズ(後天性免疫不全症候1(1)が全
世界的な問題となっている。現在までのところ片動な治
療薬は見出されていないが、エイズの性格上、多糖体等
の免疫増強剤はその発症予防や治療にある程度有効であ
ると思われる。On the other hand, in recent years, AIDS (acquired immunodeficiency syndrome 1 (1)) has become a worldwide problem. To date, no effective treatment has been found, but due to the nature of AIDS, polysaccharide Immune-enhancing agents such as these seem to be effective to some extent in preventing and treating the onset of the disease.
そこで新規でより有効な免疫増強剤を得るべく種々の酵
母及び生薬から抽出した多糖体画分の免疫系に及ぼす影
響をマイト−ジエン活性(リンパ球の幼若化反応)を指
標として検討を行った。Therefore, in order to obtain a new and more effective immune enhancer, we investigated the effects of polysaccharide fractions extracted from various yeasts and crude drugs on the immune system using mitogen activity (lymphocyte blastogenesis) as an indicator. Ta.
その結果は草から酢酸酸性下で抽出される両分、特にア
フガニスタン産の甘草(以下アフガンは草と略; G1
7c7+rhixa glabla)の熱水抽出物を除
タンパクしアルコールで沈殿させたものを、さらに酢酸
で抽出して得られる両分(以下AL−4と略)に強いマ
イト−ジエン活性を認めた。 さらに、AL−4には抗
体産生を促進する作用やマクロファージを活性化する作
用があることを見出した。The results showed that the components extracted from grass under acetic acid acidity, especially licorice from Afghanistan (hereinafter afghan abbreviated as grass; G1)
7c7+rhixa glabla) was deproteinized and precipitated with alcohol, and then extracted with acetic acid. Strong mitodiene activity was observed in both fractions (hereinafter abbreviated as AL-4). Furthermore, it was discovered that AL-4 has an effect of promoting antibody production and an effect of activating macrophages.
なお、AL−4は分析の結果、ガラクツロン酸を主体と
しラムノース、アラビノース、ガラクトースの他数種の
糖を含むヘテロ酸性多糖が主成分であり、その他にグル
カン、着色成分を含むものである(第1図、第2図)。As a result of analysis, AL-4 is mainly composed of heteroacidic polysaccharide containing galacturonic acid and several other sugars such as rhamnose, arabinose, and galactose, and also contains glucan and coloring components (Figure 1). , Figure 2).
以前、1r草から抽出した中性多糖が免疫増強作用を示
すことが、千葉大の熊谷らによって報告されているが[
和漢薬、I+、 79 (1978)]、AL−4をD
EAEセルロファインカラムで分画精製し、酸性多糖の
みにしたものにも強い免疫増強活性が認められる事から
明らかに異なるものである。Previously, Kumagai et al. of Chiba University reported that neutral polysaccharides extracted from 1R grass exhibit immune-enhancing effects.
Japanese and Chinese Medicine, I+, 79 (1978)], AL-4 as D
It is clearly different from the fact that a strong immunoenhancing activity is observed even when the acidic polysaccharide alone is fractionated and purified using an EAE Cellulofine column.
以上の結果から、甘草、特にアフガンは草の酸性多糖及
びこれを含む両分は強く免疫系を活性化する作用がある
ことが判明し、本発明を完成した。参考としてAL−4
及び分画精製した酸性多糖の赤外チャートを示した。From the above results, it has been found that the acidic polysaccharide of licorice, especially afghan grass, and the components thereof have a strong effect of activating the immune system, and the present invention has been completed. AL-4 for reference
and an infrared chart of the fractionated and purified acidic polysaccharide.
本発明におけるAL−4のマイト−ジエン活性、抗体産
生促進活性、マクロファージ活性化の試験方法ならびに
その結果を以下に示す。The test methods and results for the mitogen activity, antibody production promoting activity, and macrophage activation of AL-4 in the present invention are shown below.
(1)マイトーン4エン活性試験
96穴プレートにマウスの肝臓細胞と試料を加え、20
時間培養した後、トリチウムチミジンを添加し、さらに
4時間培養する。そして細胞を濾紙上に採取し、細胞に
取り込まれたトリチウムを液体シンチレーションカウン
ターで測定することによりマイト−ジエン活性を判定し
た。なお、マイト−ジエン活性物質としてConA (
コンカチバリンA)とLPS(リポ多糖)と比較した。(1) Mytone 4 Enactivity Test Add mouse liver cells and samples to a 96-well plate,
After culturing for an hour, tritium thymidine is added and the culture is further cultured for 4 hours. Then, the cells were collected on a filter paper, and the tritium incorporated into the cells was measured using a liquid scintillation counter to determine the mitogen activity. In addition, ConA (
Concativalin A) and LPS (lipopolysaccharide) were compared.
糖の分析は、トリフルオロ酢酸処理後、液体クロマトグ
ラフィーによりそれぞれ同定した。また分解してないも
のについて!′C−NMRを測定し解析の参考とした。Sugars were identified by liquid chromatography after treatment with trifluoroacetic acid. Also about things that haven't been disassembled! 'C-NMR was measured and used as a reference for analysis.
マイト−ジエン活性は、コントロールを1とした時のト
リチウムチミジンの取り込みで示す。Mito-diene activity is expressed as tritiated thymidine incorporation relative to control.
結果を表1に示す。The results are shown in Table 1.
表 1
試料(μg/ml) マイト−ジエン活性AL−4
12〜4
1010〜20
100 30〜50
新種は草多糖 1 1〜2
10 5〜10
100 10〜20
ConA 2 211−40LP8
5 15〜30
表1に示した結果から、AL−4に強いマイトーンエン
活性があることが明らかとなった。しかもその活性は、
ConAやLPSの至適活性よりも優れているものと推
定された。Table 1 Sample (μg/ml) Mito-diene activity AL-4
12-4 1010-20 100 30-50 New species is grass polysaccharide 1 1-2 10 5-10 100 10-20 ConA 2 211-40LP8
5 15-30 From the results shown in Table 1, it became clear that AL-4 had strong mitonene activity. Moreover, its activity is
It was estimated that this activity was superior to the optimal activity of ConA and LPS.
また同様の条件で調製した中国新種産の甘草よりの試料
と比べ2倍以上強い活性を示した。It also showed more than twice the activity as a sample from a new type of Chinese licorice prepared under similar conditions.
(1)抗体産生促進活性試験
96穴プレートにマウスの肝臓細胞と試料を加え、48
時間培養した後、培養上清を採取する。そして、その培
養上清中の抗体(IgM)をEL I SA法で定量す
ることにより判定した。(1) Antibody production promotion activity test Add mouse liver cells and samples to a 96-well plate,
After culturing for an hour, collect the culture supernatant. The determination was made by quantifying the antibody (IgM) in the culture supernatant using the ELISA method.
結果を表2に示す。The results are shown in Table 2.
表2
AL−41gM量
(Ig/wl) (ng/gl)
020〜60
150〜100
10 200〜400
+00 > 500
表2に示した結果から、AL−4は抗体産生を促進する
作用があることがわかった。Table 2 AL-41gM amount (Ig/wl) (ng/gl) 020-60 150-100 10 200-400 +00 > 500 From the results shown in Table 2, AL-4 has the effect of promoting antibody production. I understand.
(3)マクロファージの活性化試験
マクロファージの活性化は、グルコースの消費促進を指
標として試験した。すなわち、チオグリコレート培地で
誘導したマウス腹くう内滲出細胞に試料を加え、24時
間後の培養上清中のグルコースを定限し、その消費率を
求めることにより、マクロファージの活性化を判定した
。(3) Macrophage activation test Macrophage activation was tested using promotion of glucose consumption as an indicator. That is, macrophage activation was determined by adding a sample to mouse intraperitoneal exudate cells induced with thioglycollate medium, limiting glucose in the culture supernatant after 24 hours, and determining its consumption rate. .
結果を表3に示す。The results are shown in Table 3.
表 3
AL−4グルコース消費率
(8g /sl ) (%)0
5〜10
1 10〜20
1010〜20
100 15〜30
表3に示した結果から、アフガンは草から抽出した酸性
多糖を主成分とするAL−4はマクロファージを活性化
する作用があることがわかった。Table 3 AL-4 glucose consumption rate (8g/sl) (%) 0
5-10 1 10-20 1010-20 100 15-30 From the results shown in Table 3, it was found that AL-4, whose main component is acidic polysaccharide extracted from Afghan grass, has the effect of activating macrophages. Ta.
以上の実験結果から明らかなように、本発明のAL−4
は種々の免疫増強作用を有することがわかった。As is clear from the above experimental results, the AL-4 of the present invention
was found to have various immune-enhancing effects.
以下、実施例により本発明の一部を例示するが、本発明
はこれに限定されるものではない。Hereinafter, a part of the present invention will be illustrated by examples, but the present invention is not limited thereto.
実施例1
アフガンIJ草根の熱水抽出物をp I−1を2,6に
調整し遠心分離にかけ、その上清をとり、pHを5,2
に調整、遠心分離により上清を得、そこにメタノールを
等量加え、遠心分離にかけ、沈殿物をとる。その沈殿物
のIN酢酸抽出物に等量のメタノールを加え、遠心分離
し、その沈殿物を水に溶解させ、透析にかけた。そして
、その透析内液よりAL−4画分を0.3%の収率で得
た。Example 1 A hot water extract of Afghan IJ grass roots was adjusted to pH 2.6, centrifuged, the supernatant was taken, and the pH was adjusted to 5.2.
After centrifugation to obtain a supernatant, add an equal amount of methanol to it, centrifuge, and collect the precipitate. An equal volume of methanol was added to an IN acetic acid extract of the precipitate, centrifuged, and the precipitate was dissolved in water and subjected to dialysis. Then, an AL-4 fraction was obtained from the dialyzed fluid at a yield of 0.3%.
このマイト−ジエン活性は、その濃度が1.10゜10
0 pg/*lの時、それぞれ2.11.34であった
(コントロールを1とした時のトリチウムチミジンの取
り込み)。This mitogen activity is due to its concentration of 1.10°10
At 0 pg/*l, they were 2.11.34, respectively (tritiated thymidine uptake when the control was set to 1).
IgMの産生量については、その濃度が1゜10、 1
00 pg/slの時、それぞれ71.303. >
500ng/m1であった(コントロールは45ng/
ml)。Regarding the amount of IgM produced, its concentration is 1°10, 1
00 pg/sl, respectively 71.303. >
500ng/ml (control was 45ng/ml).
ml).
マクロファージのグルコースの消費については、その濃
度が1.10.100 ag/置装の時、それぞれ13
. 15.18%であった(コントロールは8%)。Regarding glucose consumption by macrophages, when its concentration is 1, 10, and 100 ag/device, respectively, 13
.. It was 15.18% (control: 8%).
実施例2
ΔL−41gをDEAE−セルロファイン300 ml
(0,05MT r i 5−HC1緩衛液pH7平
衡化)に吸着させた後、0.IMNaClで溶出してく
る両分を集め透析脱塩し約500 mgの酸性多糖を得
た。Example 2 ΔL-41g was added to DEAE-Cellulofine 300ml
(0.05M T r i 5-HC1 gentle sanitation solution pH 7 equilibration). Both fractions eluted with IMNaCl were collected and desalted by dialysis to obtain about 500 mg of acidic polysaccharide.
このものはDEAE−セファデックスカラム0〜0.5
MNa(lグラジェント溶出で単一ピークを示すもので
あった。This is a DEAE-Sephadex column 0-0.5
MNa(l) gradient elution showed a single peak.
またガラクツロン酸を標準としたカルバゾール硫酸法に
よる定量で53.2%のガラクツロン酸含凰であった。Further, the content of galacturonic acid was 53.2% as determined by the carbazole sulfuric acid method using galacturonic acid as a standard.
これのマイト−ジエン活性はその濃度力月0゜100
ag/slの時それぞれ13.35であった(コントロ
ールを1とした時のトリチウムチミジンの取り込み)。The mitodiene activity of this is that its concentration is 0°100.
ag/sl was 13.35 (incorporation of tritiated thymidine when the control was set to 1).
またIgMの産生量はその濃度が10゜IQ[l o#
の時それぞれ350. > 500ng/mlであった
。In addition, the amount of IgM produced is determined by its concentration at 10°IQ [l o#
350. >500 ng/ml.
第1図゛は実施例1のAL−4画分のI Rを示す図表
であり、第2図は実施例2の分画精製した酸性多糖のt
Rを示す図表である。FIG. 1 is a chart showing the IR of the AL-4 fraction of Example 1, and FIG. 2 is a chart showing the IR of the fractionated and purified acidic polysaccharide of Example 2.
It is a chart showing R.
Claims (4)
。(1) An immune enhancer whose main component is an acetic acid extract of licorice.
a gl−abla)の酢酸抽出物を主構成要素とする
請求項1記載の免疫増強剤。(2) Glycyrrhiz from Afghanistan
The immune enhancer according to claim 1, comprising an acetic acid extract of A. agl-abla) as a main component.
a gl−abla)の酸性多糖を主構成要素とする請
求項3記載の免疫増強剤。(4) Glycyrrhiz from Afghanistan
4. The immune enhancer according to claim 3, which contains an acidic polysaccharide of Agl-Abla) as a main component.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1119497A JP2918564B2 (en) | 1989-05-12 | 1989-05-12 | Immune enhancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1119497A JP2918564B2 (en) | 1989-05-12 | 1989-05-12 | Immune enhancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02300136A true JPH02300136A (en) | 1990-12-12 |
JP2918564B2 JP2918564B2 (en) | 1999-07-12 |
Family
ID=14762731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1119497A Expired - Fee Related JP2918564B2 (en) | 1989-05-12 | 1989-05-12 | Immune enhancer |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2918564B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05262658A (en) * | 1992-03-23 | 1993-10-12 | Nippon Paper Ind Co Ltd | Immunostimulant |
JP2001240549A (en) * | 2000-03-01 | 2001-09-04 | Pola Chem Ind Inc | Immunopotentiator and composition containing the same |
WO2012108347A1 (en) * | 2011-02-07 | 2012-08-16 | 森川健康堂株式会社 | Method for producing innate immunity activator having enhanced innate immunity promoting activity, and royal jelly-derived innate immunity activator which is produced by the production method |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101331668B1 (en) * | 2011-07-14 | 2013-11-20 | 손호장 | Method for Manufacturing the Enzymes-Veniger |
-
1989
- 1989-05-12 JP JP1119497A patent/JP2918564B2/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05262658A (en) * | 1992-03-23 | 1993-10-12 | Nippon Paper Ind Co Ltd | Immunostimulant |
JP2001240549A (en) * | 2000-03-01 | 2001-09-04 | Pola Chem Ind Inc | Immunopotentiator and composition containing the same |
WO2012108347A1 (en) * | 2011-02-07 | 2012-08-16 | 森川健康堂株式会社 | Method for producing innate immunity activator having enhanced innate immunity promoting activity, and royal jelly-derived innate immunity activator which is produced by the production method |
JP2012162488A (en) * | 2011-02-07 | 2012-08-30 | Genome Soyaku Kenkyusho:Kk | Production method for natural immunity activator enhanced in natural immunity promoting action and royal jelly-derived natural immunity activator produced by the production method |
Also Published As
Publication number | Publication date |
---|---|
JP2918564B2 (en) | 1999-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xie et al. | Polysaccharide from alfalfa activates RAW 264.7 macrophages through MAPK and NF-κB signaling pathways | |
Inngjerdingen et al. | Bioactive pectic polysaccharides from Glinus oppositifolius (L.) Aug. DC., a Malian medicinal plant, isolation and partial characterization | |
Leung et al. | The isolation and characterization of an immunomodulatory and anti-tumor polysaccharide preparation from Flammulina velutipes | |
CN110437288B (en) | Sea cucumber fucoidin and preparation method and application thereof | |
CN107698689B (en) | Method for extracting polysaccharide from houttuynia cordata | |
JP4010768B2 (en) | A new pectic polysaccharide purified from Angelica, Gigas and Nakai, its purification method and its use as an immunostimulant | |
US20110207921A1 (en) | Sulfated derivative of gastrodia elata polysaccharide, preparation method and antitumor use thereof | |
JP2022544723A (en) | Homogeneous polysaccharide with sashimi and its preparation method and application | |
DE60307500T2 (en) | POLYSACCHARIDE OF ECHINACEA ANGUSTIFOLIA | |
CN104844727B (en) | Rose acidity pectin polysaccharide and its production and use | |
JP6034293B2 (en) | Epimedium polysaccharide, its fractions, and its use as a vaccine adjuvant | |
JP6681466B2 (en) | Homogeneous polysaccharide having immunomodulatory activity and method for preparing the same | |
EP0475383B1 (en) | Polysaccharide composition or polysaccharide having heparinoid activity, process for producing the same, and anticoagulant containing the same as active ingredient | |
Liz et al. | The anti‐inflammatory modulatory role of Solidago chilensis Meyen in the murine model of the air pouch | |
JPH02300136A (en) | Immunological enhancing agent | |
Lu et al. | Structural characterization and anti-complementary activities of two polysaccharides from Houttuynia cordata | |
Dewey et al. | Studies on suramin (Antrypol: Bayer 205): 5. The combination of the drug with the plasma and other proteins | |
AU686161B2 (en) | Remitting agent for nephrotic syndrome and hepatopathy symptoms | |
CA1339111C (en) | Antiviral agent | |
KR970011556B1 (en) | Purification method of fomitella fraxinea rdagb 129 extracts | |
CN112107590B (en) | Application of swim bladder-derived heparin mucopolysaccharide in preparation of angiogenesis inhibitor | |
WO2014173057A1 (en) | Trametes robiniophila polysaccharide protein, preparation method therefor, and application thereof | |
WO2014173056A1 (en) | Trametes robiniophila polysaccharide protein, preparation method therefor, and application thereof | |
JPH07238030A (en) | Hypoglycemic agent | |
CN105708851B (en) | The more carbohydrates and their derivatives of cordate houttuynia are preparing the purposes in Complement inhibition drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |